BIIB - PR: FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease -LEQEMBI
BIIB - PR: FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease -LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) -U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 Link To Press Release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.